181 related articles for article (PubMed ID: 36907641)
1. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
Rigaud C; Knörr F; Brugières L; Woessmann W
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
3. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
5. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series.
Ruf S; Hebart H; Hjalgrim LL; Kabickova E; Lang P; Steinbach D; Schwabe GC; Woessmann W
Pediatr Blood Cancer; 2018 Jun; 65(6):e27003. PubMed ID: 29512859
[TBL] [Abstract][Full Text] [Related]
6. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.
Brugières L; Cozic N; Houot R; Rigaud C; Sibon D; Arfi-Rouche J; Bories P; Cottereau AS; Delmer A; Ducassou S; Garnier N; Lamant L; Leruste A; Millot F; Moalla S; Morschhauser F; Nolla M; Pagnier A; Reguerre Y; Renaud L; Schmitt A; Simonin M; Verschuur A; Hoog Labouret N; Mahier Ait Oukhatar C; Vassal G
Eur J Cancer; 2023 Sep; 191():112984. PubMed ID: 37549532
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A; Soma L
Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
[TBL] [Abstract][Full Text] [Related]
9. Leukaemic relapse of anaplastic large cell lymphoma, ALK negative.
Karki NR; Badin K; Savage N; Bryan L
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33619137
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic large cell lymphoma: a single institution experience from India.
Lakshmaiah KC; Guruprasad B; Shah A; Kavitha S; Abraham LJ; Govindbabu K; Aruna Kumari BS; Appaji L
J Cancer Res Ther; 2013; 9(4):649-52. PubMed ID: 24518711
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.
Damm-Welk C; Pillon M; Woessmann W; Mussolin L
Front Biosci (Schol Ed); 2015 Jun; 7(2):205-16. PubMed ID: 25961696
[TBL] [Abstract][Full Text] [Related]
12. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma.
Damm-Welk C; Mussolin L; Zimmermann M; Pillon M; Klapper W; Oschlies I; d'Amore ES; Reiter A; Woessmann W; Rosolen A
Blood; 2014 Jan; 123(3):334-7. PubMed ID: 24297868
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925
[TBL] [Abstract][Full Text] [Related]
15. ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient.
Pulitzer M; Ogunrinade O; Lin O; Steinherz P
J Cutan Pathol; 2015 Mar; 42(3):182-187. PubMed ID: 25404214
[TBL] [Abstract][Full Text] [Related]
16. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
18. Detection of TRAF1-ALK fusion in skin lesions of systemic ALK+ anaplastic large cell lymphoma initially involving the skin and the draining lymph node.
Norimatsu Y; Akatsuka T; Matsuoka A; Hamada T; Mori I; Shiomi T; Mori N; Onishi K; Togashi Y; Inoue N; Takeuchi K; Sugaya M
J Dermatol; 2024 Jan; 51(1):120-124. PubMed ID: 37753577
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
20. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
